sponsored
PatientsVille.com Logo

PatientsVille

Forsteo Medical Research Studies

Up-to-date List of Forsteo Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Forsteo Medical Research Studies

Rank Status Study
1 Recruiting Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
Condition: Osteoporosis
Intervention: Drug: Teriparatide
Outcome Measures: Volumetric bone mineral density (BMD) of the lumbar spine (mg hydroxyapatite/cm3);   Lumbar spine, total hip and whole body bone mineral density (g/cm2);   Biochemical markers of bone turnover;   Distal tibia and radius volumetric body bone mineral density (BMD) (mg hydroxyapatite/cm3)
2 Recruiting The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab
Condition: Osteoporosis Treatment
Interventions: Drug: 18 months teriparatide followed by 18 months denosumab;   Drug: three separate 6 month cycles of daily teriparatide, each followed by one of denosumab
Outcome Measures: spine bone density;   bone mineral density of the hip, wrist, total body and lateral spine and CT of arm and leg
3 Recruiting Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
Condition: Osteoporosis
Intervention: Drug: Teriparatide
Outcome Measure: Change in cortical thickness at the radius and tibia as measured by high-resolution quantitative computer tomography (HR-pQCT)
4 Recruiting Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
Condition: Adult Idiopathic Generalized Osteoporosis
Interventions: Drug: Teriparatide;   Drug: Saline Placebo
Outcome Measure: Change in lumbar spine bone mineral density (LS-BMD)
5 Not yet recruiting Nasally and sc Administered Teriparatide in Healthy Volunteers
Condition: Osteoporosis
Interventions: Drug: Forsteo;   Drug: CP046 PTH CriticalSorb
Outcome Measures: Area under the plasma concentration time curve (AUC) of teriparatide for six hours after each single administration.;   Peak plasma concentration (cmax) of teriparatide for six hours after each single administration.;   The percentage of radiolabelled formultation deposited and cleared from the nose measured by gamma scintigraphy
6 Not yet recruiting Teriparatide for Fracture Repair in Humans
Conditions: Osteoporosis, Age-Related;   Humeral Fractures
Interventions: Drug: Teriparatide;   Drug: Placebo
Outcome Measures: Identification of bone and callus patterns in the CT data at the fracture site;   Finite Element Analysis (FEA) of QCT (quantitative computed tomography) data
7 Recruiting Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion
Conditions: Lumbar Spondylosis;   Lumbar Spondylolisthesis;   Adult Degenerative Lumbar Scoliosis
Intervention: Biological: teriparatide
Outcome Measures: Quality of spine fusion;   Time to spine fusion;   Clinical outcome;   Adverse effects
8 Recruiting Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis
Condition: Osteoporosis
Intervention: Drug: Teriparatide
Outcome Measures: BMD at Hip and lumber spine;   Reduction in fracture risk
9 Recruiting Fracture (FX) Improvement With Teriparatide: FiX-IT Study
Conditions: Osteoporosis;   Atypical Femoral Fracture
Intervention: Drug: teriparatide
Outcome Measures: Radiologic evidence of healing;   Radiologic healing;   Increased bone density;   Quality of Life improvements;   Difference in biochemical markers of bone turnover
10 Recruiting Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures
Condition: Non Displaced Atypical Femoral Fractures
Intervention: Biological: Teriparatide 20 mcg
Outcome Measures: Change in the modified The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)of the affected limb (the femur that has the incomplete AFF);   The proportion of patients requiring surgical intervention
11 Recruiting The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Condition: Osteogenesis Imperfecta
Interventions: Drug: Zoledronic acid;   Drug: Teriparatide;   Drug: placebo zoledronic acid;   Drug: placebo teriparatide
Outcome Measures: Bone Mineral Density (BMD);   Fracture risk
12 Recruiting Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
Condition: Postmenopausal Osteoporosis
Intervention: Drug: Teriparatide 40-mcg subcutaneous injection
Outcome Measure: Bone turnover marker (blood sample)
13 Unknown  The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures
Condition: Fractures
Interventions: Drug: Teriparatide;   Drug: Placebo
Outcome Measures: Fracture healing;   Pain;   Range of Motion;   Function;   Return to Activity
14 Recruiting Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
Condition: Rheumatoid Arthritis
Intervention: Drug: Teriparatide
Outcome Measures: Joint Erosion by 3D CT scan;   Lumbar by DXA
15 Recruiting A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)
Condition: Low Bone Mass in Anorexia Nervosa Patients
Intervention: Drug: osteoanabolic therapy
Outcome Measure: To assess the efficacy of Teriparatide (Forsteo®) in increasing the bone mineral density in the lumbar spine, total hip and femoral neck in patients with anorexia nervosa and low bone density at months 12 and 24.
16 Recruiting VERtebral Fracture Treatment Comparisons in Osteoporotic Women
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Teriparatide;   Drug: Risedronate;   Drug: Placebo;   Drug: Calcium;   Drug: Vitamin D
Outcome Measures: Proportion of Participants with New Vertebral Fractures;   Proportion of Participants with Pooled New and Worsening Vertebral Fractures;   Proportion of Participants with Pooled Clinical Vertebral and Non-Vertebral Fragility Fractures;   Proportion of Participants with Non-Vertebral Fragility Fractures;   Proportion of Participants with Major Non-Vertebral Fragility Fractures;   Proportion of Participants with New Moderate and/or Severe Vertebral Fractures;   Proportion of Participants with New Multiple (2 or more) Vertebral Fractures;   Proportion of Participants with Pooled Fragility and Traumatic Non-Vertebral Fractures;   Change from Baseline to 24 Months Endpoint in Height;   Change from Baseline to 24 Month Endpoint in Back Pain using an 11-point Numerical Pain Rating Scale;   Change from Baseline to 24 Month Endpoint in the European Quality of Life Questionnaire [EQ-5D-5L]
17 Recruiting Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?
Condition: Spinal Stenosis
Intervention: Drug: Teriparatide
Outcome Measure: The rate of bone healing after spinal stenosis surgery
18 Recruiting Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur
Condition: Osteoporosis
Interventions: Drug: Teriparatide;   Other: placebo
Outcome Measures: Bone formation rate;   Blood samples will be analyzed for indices of bone formation (serum P1NP) and resorption (serum CTX) after treatment with placebo or teriparatide Biochemical markers of bone
19 Recruiting Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
Condition: Osteoporosis
Interventions: Drug: Denosumab treatment in osteoporotic patients;   Drug: Teriparatide treatment in osteoporotic patients;   Drug: Denosumab and teriparatide treatment in osteoporotic patients
Outcome Measures: Changes of bone mineral density;   Changes of bone turnover markers
20 Recruiting Effects of Teriparatide Therapy for Japanese
Condition: Osteoporosis
Intervention:
Outcome Measures: The determinants related to BMD increase and fracture prevention for teriparatide treatment;   BMD and BTMs response, and fracture prevention effects of teriparatide for the patients in nursing home

These studies may lead to new treatments and are adding insight into Forsteo etiology and treatment.

A major focus of Forsteo research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Forsteo